Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

NCT00080899 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions

DRUG: fenretinide
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)